Browsing Tag
Palvella Therapeutics
3 posts
Palvella Therapeutics targets first approved microcystic lymphatic malformation therapy with QTORIN filing
Palvella Therapeutics completes its QTORIN FDA filing and prepares for a potential 2027 launch in microcystic lymphatic malformations.
Palvella Therapeutics (NASDAQ: PVLA) rebounds 15% as investors reassess FDA path
Palvella Therapeutics is recovering from a sharp selloff as investors separate its advancing QTORIN rolling application from uncertainty surrounding a second indication.
FDA doubles down on Palvella’s QTORIN rapamycin as Phase 3 SELVA trial exceeds enrollment
Find out how the FDA’s renewed orphan grant is accelerating Palvella Therapeutics’ Phase 3 QTORIN trial toward potential approval in rare disease care.